Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages

被引:128
|
作者
Schöler, N
Olbrich, C
Tabatt, K
Muller, RH
Hahn, H
Liesenfeld, O
机构
[1] Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Infect Med, Dept Med Microbiol & Immunol Infect, D-12203 Berlin, Germany
[2] Free Univ Berlin, Dept Pharmaceut Biopharmaceut & Biotechnol, D-12169 Berlin, Germany
关键词
solid lipid nanoparticles; surfactant; surface modification; size; peritoneal macrophages; cytokines; cytotoxicity;
D O I
10.1016/S0378-5173(01)00660-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
After intravenous (i.v.) injection, solid lipid nanoparticles (SLN) interact with mononuclear cells. Murine peritoneal macrophages were incubated with SLN formulations consisting of Dynasan 114 coated with different surfactants. The present study was performed to examine the impact of surfactants, which are important surface defining components of SLN, on viability and cytokine production by macrophages. Cytotoxicity, as assessed by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) test, was strongly influenced by the surfactant used being marked with cetylpyridinium chloride- (CPC-) coated SLN at a concentration of 0.001%, and further increased at SLN concentrations of 0.01 and 0.1%. All other SLN formulations - containing Poloxamine 908 (P908), Poloxamer 407 (P407), Poloxamer 188 (P188), Solutol HS15 (HS15), Tween 80 (T80), Lipoid S75 (S75), sodium cholate (SC), or sodium dodecylsulfate (SDS) - when used at the same concentrations reduced cell viability only slightly. None of the SLN formulations tested induced cytokine production but a concentration-dependent decrease of IL-6 production was observed, which appeared to be associated with cytotoxic effects. IL-12 and TNF-alpha were detected neither in supernatants of macrophages treated with SLN at any concentration nor in those of untreated cells. In contrast to the type of surfactant, the size of SLN was found neither to affect cytotoxicity, of SLN nor to result in induction or digression of cytokine production by macrophages. In conclusion, testing the effects of surfactants on SLN on activity of macrophages is a prerequisite prior to in vivo use of SLN, (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:57 / 67
页数:11
相关论文
共 50 条
  • [31] In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)
    Costa, Claudia Pina
    Barreiro, Sandra
    Moreira, Joao Nuno
    Silva, Renata
    Almeida, Hugo
    Sousa Lobo, Jose Manuel
    Silva, Ana Catarina
    PHARMACEUTICALS, 2021, 14 (08)
  • [32] Oral bioavailability of cyclosporine:: Solid lipid nanoparticles (SLN®) versus drug nanocrystals
    Mueller, R. H.
    Runge, S.
    Ravelli, V.
    Mehnert, W.
    Thuenemann, A. F.
    Souto, E. B.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 317 (01) : 82 - 89
  • [33] Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
    Uner, Melike
    Yener, Guelguen
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (03): : 289 - 300
  • [34] Solid lipid nanoparticles (SLN) for controlled drug delivery -: a review of the state of the art
    Müller, RH
    Mäder, K
    Gohla, S
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (01) : 161 - 177
  • [35] Drug-Lipid-Surfactant Miscibility for the Development of Solid Lipid Nanoparticles
    Trivino, Anne
    Gumireddy, Ashwini
    Chauhan, Harsh
    AAPS PHARMSCITECH, 2019, 20 (02)
  • [36] Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407
    Muller, RH
    Maassen, S
    Weyhers, H
    Mehnert, W
    JOURNAL OF DRUG TARGETING, 1996, 4 (03) : 161 - 170
  • [37] Drug-Lipid-Surfactant Miscibility for the Development of Solid Lipid Nanoparticles
    Anne Trivino
    Ashwini Gumireddy
    Harsh Chauhan
    AAPS PharmSciTech, 20
  • [38] Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for the delivery of bioactives sourced from plants: part I - composition and production methods
    Fathi, Faezeh
    Machado, Tatiane O. X.
    Kodel, Helena de A. C.
    Portugal, Isabella
    Ferreira, Ines O.
    Zielinska, Aleksandra
    Oliveira, M. Beatriz P. P.
    Souto, Eliana B.
    EXPERT OPINION ON DRUG DELIVERY, 2024, 21 (10) : 1479 - 1490
  • [39] Formulations based on solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for cutaneous use: A review
    Garces, A.
    Amaral, M. H.
    Sousa Lobo, J. M.
    Silva, A. C.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 112 : 159 - 167
  • [40] Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC) for pulmonary application: A review of the state of the art
    Weber, S.
    Zimmer, A.
    Pardeike, J.
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2014, 86 (01) : 7 - 22